bosentan anhydrous has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbetakis, NG; Bischiniotis, TS; Ilonidis, GC; Lafaras, CT; Mandala, EM; Paraskevopoulos, PP; Platogiannis, DN; Saratzis, AN | 1 |
| Lalich, M; Liu, G; McNeel, DG; Wilding, G | 1 |
1 review(s) available for bosentan anhydrous and Cancer of Ovary
| Article | Year |
|---|---|
Endothelin receptor antagonists in cancer therapy.
Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides | 2007 |
1 other study(ies) available for bosentan anhydrous and Cancer of Ovary
| Article | Year |
|---|---|
Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bosentan; Carcinoid Heart Disease; Combined Modality Therapy; Echocardiography, Doppler; Endothelin Receptor Antagonists; Exercise Test; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Natriuretic Peptide, Brain; Ovarian Neoplasms; Peptide Fragments; Sulfonamides | 2010 |